Bispecific Antibody Market Players:
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Innovent Biologics, Ltd.
- Affimed GmbH
- Pieris Pharmaceuticals, Inc.
- Mereo BioPharma Group plc
- TG Therapeutics, Inc.
- MacroGenics, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- AbbVie, Inc.
- Roche
- Sanyou Biopharmaceuticals Co., Ltd.
- Orion Corporation
- Amgen Inc.
The presence of research-based key pharma developers is expanding the pipeline of the market. They are competitively innovating new therapeutics and identifying extended indications to solidify their leadership. For instance, in May 2024, Amgen attained FDA approval for its Imdelltra (tarlatamab-dlle) in treating extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. In the same timeframe, Regeneron Pharmaceuticals achieved positive endpoints phase 1/2 trial on its first-in-class costimulatory bispecific antibody, REGN7075 (EGFRxCD28), in combination with Libtayo (cemiplimab) for treating patients with advanced solid tumors. This cohort of pioneers includes:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of bispecific antibody is assessed at USD 20.7 billion.
The global bispecific antibody market size was around USD 20.7 billion in 2026 and is likely to expand at a CAGR of more than 39.6%, surpassing USD 581.87 billion revenue by 2036.
The North America bispecific antibody market is projected to capture a 35% share by 2036, driven by rising adoption of targeted therapies and favorable regulatory support.
Key players in the market include F. Hoffmann-La Roche Ltd., Innovent Biologics, Ltd., Affimed GmbH, Pieris Pharmaceuticals, Inc., Mereo BioPharma Group plc, TG Therapeutics, Inc., MacroGenics, Inc., Pfizer Inc., GlaxoSmithKline plc, AbbVie, Inc.
